Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital, Research Institute, 281/289 Rzgowska St, 93-338, Lodz, Poland.
Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, 281/289 Rzgowska St., 93-338, Lodz, Poland.
Rev Endocr Metab Disord. 2021 Dec;22(4):1027-1039. doi: 10.1007/s11154-021-09648-y. Epub 2021 May 5.
Subacute thyroiditis (SAT) is a thyroid inflammatory disease, whose pathogenesis and determinants of the clinical course were unclear for many decades. The last few years have brought many clinically significant new data on the epidemiology, pathogenesis and management of SAT. Several human leukocyte antigen (HLA) alleles were demonstrated not only to increase the risk of SAT, but also to correlate with SAT clinical course and determine the risk of recurrence. The world-wide epidemic of the coronavirus disease 19 (COVID-19) has provided new observations that the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can be a potent SAT-triggering factor, and that the clinical course of SAT in patients affected by COVID-19 is different from a typical one. Additionally, many new trends in the clinical course are emerging. In the last years, painless course of SAT is more and more often described, constituting a special challenge in patients hospitalized due to COVID-19. Despite an excellent availability of diagnostic methods, several difficulties in SAT differential diagnosis can be currently encountered and the proper diagnosis and treatment is frequently delayed. False positive diagnoses of SAT in patients with malignancies of poor prognosis constitute a life-threatening problem. Taking into account all the new aspects of SAT pathogenesis and of its clinical course, the new - modified - SAT diagnosis criteria have been proposed.
亚急性甲状腺炎(SAT)是一种甲状腺炎症性疾病,其发病机制和临床病程的决定因素在几十年里都不明确。在过去的几年里,人们获得了许多关于 SAT 的流行病学、发病机制和治疗的具有重要临床意义的新数据。有几个人类白细胞抗原(HLA)等位基因不仅被证明会增加 SAT 的风险,而且还与 SAT 的临床病程相关,并决定了复发的风险。全球范围内的 2019 冠状病毒病(COVID-19)大流行提供了新的观察结果,即严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)可能是 SAT 的一个强有力的触发因素,COVID-19 患者的 SAT 临床病程与典型病程不同。此外,许多新的临床病程趋势正在出现。在过去几年中,越来越多地描述了 SAT 的无痛病程,这在因 COVID-19 住院的患者中构成了一个特殊的挑战。尽管诊断方法非常完备,但目前在 SAT 的鉴别诊断中可能会遇到一些困难,并且诊断和治疗经常被延误。预后不良的恶性肿瘤患者中 SAT 的假阳性诊断构成了危及生命的问题。考虑到 SAT 发病机制和临床病程的所有新方面,提出了新的——经过修改的——SAT 诊断标准。